ライフサイエンスコーパス: glycemia

1 eriod, respiratory period, body temperature, glycemia).

2 y disease independent of kidney function and glycemia.

3 insulin sensitivity, insulin secretion, and glycemia.

4 f the GLP-1 receptor on gastric emptying and glycemia.

5 insulin analogs for the prandial control of glycemia.

6 h type 1 diabetes before and after improving glycemia.

7 on, heightened insulin levels, and decreased glycemia.

8 oxylase protein levels related strongly with glycemia.

9 uppresses gluconeogenic genes and normalizes glycemia.

10 k1/2 signaling, and the potential effects on glycemia.

11 release, gastric emptying, and postprandial glycemia.

12 sponse, insulin sensitivity, and measures of glycemia.

13 t that this might not reflect differences in glycemia.

14 ntegrated measures of circulating nonfasting glycemia.

15 s equivocal effect of PPAR-alpha agonists on glycemia.

16 cipal determinant of risk was the history of glycemia.

17 adiposity, particularly leptin, and maternal glycemia.

18 eline kidney function but not independent of glycemia.

19 ding on the treatment and the instability of glycemia.

20 so affected locomotor activity and levels of glycemia.

21 tment improved glucose tolerance and fasting glycemia.

22 e, hyperinsulinemia, dyslipidemia, and hyper-glycemia.

23 nsulin signaling, surprisingly showed normal glycemia.

24 ed adipose tissue thermogenesis and improved glycemia.

25 as a tonic insulin antagonist in regulating glycemia.

26 isease to a degree rather than just palliate glycemia.

27 develop progressive disease despite lowering glycemia.

28 ulin levels, and greatly decreased levels of glycemia.

29 GF21, which include weight loss and improved glycemia.

30 y which exenatide can attenuate postprandial glycemia.

31 or reduce the production of GLP1 and affect glycemia.

32 did not lead to production of GLP1 or reduce glycemia.

33 issue function and the maintenance of normal glycemia.

34 both contribute to observed improvements in glycemia.

35 ate the association between dairy intake and glycemia.

36 on, restored insulin secretion, and improved glycemia.

37 high-fat diet-induced elevations in fasting glycemia.

38 centage of weight gain but did not influence glycemia.

39 of starch has implications for postprandial glycemia.

40 e, thereby lowering fasting and postprandial glycemia.

41 no differences in the incidence of impaired glycemia (16% in the probiotic group compared with 15% i

42 d control subjects reached similar nadirs of glycemia (45 +/- 3 and 41 +/- 1 mg/dl, respectively) dur

43 blood versus 733 +/- 277 mug/L (P < 0.0001), glycemia 5.44 +/- 0.7 versus 5.49 +/- 0.7 mmol/L (P = 0.

44 r studies have addressed whether near-normal glycemia (80-110 mg/dl) in this clinical setting improve

45 was negatively associated with a measure of glycemia (A1C; r = -0.44, P = 0.006) and positively asso

46 ic dogs resulted in normalization of fasting glycemia, accelerated disposal of glucose after oral cha

47 Prospective consumption (P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10)

48 and near-normal postprandial insulinemia and glycemia after correcting excessive postprandial hypergl

49 ontrolled trials measuring peak postprandial glycemia after isoenergetic replacement of glucose, sucr

50 c insulin action decreases fasting glycemia, glycemia after pyruvate injection, and PEPCK protein exp

51 Normalization of glycemia after SPK shows no significant improvement in n

52 They can normalize glycemia after transplantation, although after a relativ

53 having 2 risk alleles and a history of poor glycemia and 1.54 (95% CI, 0.72-3.30) for participants w

54 .8% of patients experienced impaired fasting glycemia and 13.4% NODAT.

55 We investigated the association of glycemia and 43 genetic risk variants for hyperglycemia/

56 OLZ-IV caused a transient increase in glycemia and a higher rate of glucose appearance (R(a))

57 a on the effect of trajectories in long-term glycemia and all-cause mortality are lacking.

58 larger increase in fasting and postprandial glycemia and basal EGP and a larger decrease in M and AI

59 r of IL-1beta, has been suggested to improve glycemia and beta-cell function in patients with type 2

60 Glycemia and beta-cell function were assessed 1 week lat

61 tabolic actions of GLP-1 enable reduction of glycemia and body weight in diabetic and obese subjects,

62 ction was evaluated by measuring not-fasting glycemia and by performing an IVGTT on days 15 and 30 po

63 suggest a strong relation between markers of glycemia and cardiovascular risk, even extending into th

64 tions despite marked postprandial changes in glycemia and circulating insulin concentrations.

65 A positive correlation was observed between glycemia and clinical attachment loss (AL), whereas a ne

66 ant reductions in the primary outcome in the glycemia and dyslipidemia trials, but no significant eff

67 DPP-4 inhibition reduced glycemia and enhanced insulin levels and the incretin ef

68 The relationship between control of glycemia and gastric emptying (GE) is unclear.

69 diabetes after accounting for preconception glycemia and gestational glucose intolerance.

70 was required for maintaining normal fasting glycemia and glucose production.

71 diabetes with periodontitis presented higher glycemia and glycated hemoglobin values in contrast to p

72 of metabolic syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycer

73 mice exhibited significantly lowered fasting glycemia and heightened hepatic insulin sensitivity.

74 cts and four continuous outcomes (reflecting glycemia and hepatic insulin resistance) in 8,271 nondia

75 n between the APOB R3527Q variant and T2D or glycemia and highlight the asymmetry of the LDL-C-T2D re

76 This reduced fasting glycemia and improved glucose tolerance.

77 ced hepatic insulin sensitivity with reduced glycemia and improved glucose tolerance.

78 PAHSA administration in mice lowers ambient glycemia and improves glucose tolerance while stimulatin

79 Treatment of obese mice with PAHSAs lowers glycemia and improves glucose tolerance while stimulatin

80 Islet transplantation normalized glycemia and increased body and muscle weight; it was al

81 Destabilization of glycemia and increases in EIR were used as signs of reje

82 Compared with IS, IR subjects showed higher glycemia and insulin hypersecretion due to greater beta-

83 ns between baseline serum 25(OH)D and future glycemia and insulin resistance.

84 tory responses in leukocytes as well as 24-h glycemia and insulin secretion were analyzed.When compar

85 PTPR-gamma loss-of-function lowers glycemia and insulinemia by enhancing insulin-stimulated

86 y, was inversely associated with measures of glycemia and insulinemia in Brazilian adults without dia

87 physical activity at decreasing postprandial glycemia and insulinemia in healthy, normal-weight adult

88 l extract of Salacia oblonga on postprandial glycemia and insulinemia in patients with type 2 diabete

89 The extract of Salacia oblonga lowers acute glycemia and insulinemia in persons with type 2 diabetes

90 Postprandial glycemia and insulinemia were measured in capillary plas

91 ression, and the use of therapies to control glycemia and lipidemia in its late stages.

92 s, have the potential to beneficially modify glycemia and long-term risks.

93 fects of endogenous GLP-1 on food intake and glycemia and may promote the further development of GLP-

94 ncreased after 10 days of hyperglycemia, and glycemia and muscle TRIB3 were both restored toward norm

95 en synthesis, with resultant improvements in glycemia and no evidence of hypoglycemia.

96 family history of diabetes and preconception glycemia and obesity.

97 The role of intermediate-term and acute glycemia and of glucose variability on microvascular and

98 hepatic gammaATP correlated negatively with glycemia and oxidized LDL.

99 y U test) and a correlation analysis between glycemia and periodontal parameters were performed (Spea

100 es, a low-fat vegan diet appeared to improve glycemia and plasma lipids more than did conventional di

101 We examined the relation between gestational glycemia and prepregnancy body mass index (ppBMI) with o

102 tive in nature, possibly fueled by worsening glycemia and regenerative processes.

103 portant contribution to long-term control of glycemia and T2DM once substantial surgery-induced weigh

104 (AL), whereas a negative correlation between glycemia and the number of teeth present was found (P <0

105 re associated longitudinally with changes in glycemia and the risk type 2 diabetes.

106 Plasmatic concentration of glycemia and TNF-alpha (n = 10) were analyzed by the glu

107 an interaction between the level of fasting glycemia and tobacco smoking.

108 ant women with GDM had beneficial effects on glycemia and total and LDL-cholesterol concentrations bu

109 essibility on postprandial metabolism (e.g., glycemia) and to gain insight into the structural and bi

110 Spontaneous physical activity, 24-h glycemia, and 24-h insulin secretion did not differ betw

111 motility, gastrointestinal hormone release, glycemia, and EI.

112 ose of leptin below that needed to normalize glycemia, and if the ability of leptin to lower plasma g

113 ce developed similar body weight, steatosis, glycemia, and insulin levels after a glucose load; howev

114 ements in intraperitoneal glucose tolerance, glycemia, and islet function and also impaired insulin s

115 ith improved metabolic control (A1c, fasting glycemia, and metabolic tests) after IAK (14,779+/-3,800

116 tion between graft functionality assessed by glycemia, and MRI signal remains unclear.

117 enal function, albumin excretion rate (AER), glycemia, and other variables, with repeat renal biopsie

118 lycemia, remain regulated by fluctuations in glycemia, and pancreatic histology was normal.

119 i.p.) during 4 weeks had decreased fat mass, glycemia, and plasma levels of triglycerides and were pr

120 fibrosis-related diabetes, two indeterminate glycemia, and six impaired glucose tolerance.

121 an white persons across the full spectrum of glycemia, and the differences increase as glucose intole

122 s at doses devoid of effects on body weight, glycemia, and the THA.

123 antropyloroduodenal pressures, gut hormones, glycemia, appetite, and energy intake in obese subjects

124 associated with type 2 diabetes and fasting glycemia are enriched in these clustered islet enhancers

125 her the effects of GIP on energy balance and glycemia are regulated by glucocorticoids using pharmaco

126 tensive therapy (n = 711) aimed at achieving glycemia as close to the nondiabetic range as safely pos

127 or diabetes-related genes, using measures of glycemia as quantitative traits in 330 pedigrees from th

128 n of OLZ resulted in a transient increase in glycemia as well as a higher R(a) in the basal period.

129 ucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and alb

130 Our results suggest that glycemia, as assessed by HbA1c, may be an important biom

131 ose was significantly lower at higher plasma glycemia, as was the appearance of d-xylose after the me

132 current study was to evaluate the effects of glycemia-associated genetic loci on islet function in vi

133 es remission at 2 years or of improvement in glycemia at 1 and 3 months.

134 ]), insulin sensitivity (Matsuda index), and glycemia at 12 months postpartum in 494 women undergoing

135 P = 0.04, eta(2) = 0.125) with a significant glycemia-awareness interaction for CRT after one hour of

136 Despite normal feeding and fasting glycemia, BG4KO mice were glucose intolerant, demonstrat

137 Controlling glycemia, blood pressure, and cholesterol is important f

138 oduction during subsequent periods of normal glycemia but too brief to affect the HbA1c value are a m

139 ovements in insulin action and reductions in glycemia, but did not correspond with reductions in oxid

140 of sucrose and thereby suppress postprandial glycemia, but the evidence in humans is limited.

141 ose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion.

142 Insulin detemir (DET) reduces glycemia comparably to other long-acting insulin formula

143 weight, food intake, energy expenditure, and glycemia compared with Cnr1(flox/flox) control mice.

144 ipr(-/-) mice had similar energy balance and glycemia compared with Gipr(+)(/+) controls.

145 is characterized by imperfect management of glycemia, consequent chronic hyperglycemia, and relentle

146 , or inflammatory cytokines, or perhaps poor glycemia control.

147 NIRKO mice revealed a glycemia-dependent impairment in the sympathoadrenal res

148 epatocyte injury and inflammation, decreased glycemia, deranged hepatic TCA cycle intermediate concen

149 raphics, risk factors, a latent variable for glycemia (diabetes status, fasting glucose, glycated hem

150 a detection limit of 50 muM (useful for hypo-glycemia disease).

151 surgical patients suggested that near-normal glycemia dramatically improved outcomes compared with mo

152 GLP-1 potently diminished postprandial glycemia during acute and intermittent regimens.

153 enhanced DNL as a glucose sink in regulating glycemia during catch-up growth, which is blunted by exp

154 In conclusion, maternal glycemia during pregnancy is associated with increased b

155 is, which is critical for the maintenance of glycemia during the adaptation to birth.

156 ments on obesity and the metabolic syndrome, glycemia, dyslipidemia, and cardiovascular risk and expl

157 ility of multiple drug classes that modulate glycemia effectively and minimize long-term complication

158 nds appropriate follow-up studies related to glycemia, end-organ complications, and graft function.

159 Ad-hACE2-eGFP significantly improved fasting glycemia, enhanced intraperitoneal glucose tolerance, in

160 Postprandial glycemia excursions increase after gastric bypass surger

161 nsulin analogs do not provide a stable basal glycemia for more than a few hours.

162 DCCT persist at certain loci associated with glycemia for several years during the EDIC Study and sup

163 This paper discusses tests of glycemia for the diagnosis of type 2 diabetes mellitus,

164 for another 2 h and then maintaining normal glycemia for the following 6 h.

165 yco-/lipoxidation, nor markers of lenticular glycemia (fructose-lysine, glucospane) were elevated by

166 mice on a chow diet exhibited normal ambient glycemia, glucose tolerance and insulin sensitivity, and

167 ypothalamic insulin action decreases fasting glycemia, glycemia after pyruvate injection, and PEPCK p

168 w-density lipoprotein cholesterol level, and glycemia had been measured during the previous year and

169 etween incident heart failure and antecedent glycemia has not been evaluated.

170 ion and structure and their association with glycemia have not been explored in type 1 diabetes (T1DM

171 essment of insulin resistance [HOMA-IR], and glycemia (HbA(1c) [A1C]) to the levels of these inflamma

172 ta-cell dysfunction, insulin resistance, and glycemia, highlighting the need for consideration of the

173 In the subgroup of patients who lost weight, glycemia, homeostasis model of assessment of insulin res

174 ated to postglucose load rather than fasting glycemia, i.e., IGT rather than IFG.

175 Glycemia improved despite more reductions in concomitant

176 ponsiveness was reversed once the control of glycemia improved.

177 on, leading to a reduction in fed and fasted glycemia, improved glucose intolerance, decreased expres

178 betes, alphagp130KO mice had reduced fasting glycemia, improved glucose tolerance, reduced fasting in

179 e association of FH with diabetes status and glycemia in a large Amish population enriched for the FH

180 us animal studies, 1B6 was poor at reversing glycemia in a model of type 1 diabetes, whereas 1F11 ind

181 The factors regulating glycemia in a setting devoid of insulin and glucagon fun

182 ble approach to improve body composition and glycemia in adults with overweight and obesity.We evalua

183 Variability of glycemia in ambulatory conditions defined as the deviati

184 vidence that FBPase inhibitors could improve glycemia in animal models of type 2 diabetes.

185 HbA1c may systematically underestimate past glycemia in black patients with SCT and may require furt

186 e infusion caused a modest increase in basal glycemia in both experimental groups, with no change in

187 ely 150 mg/dl is not inferior to near-normal glycemia in critically ill patients requiring nutrition

188 SSTR2 antagonism does not affect basal glycemia in D rats.

189 Assessing glycemia in diabetes can be a challenge, but approaches

190 vitamin D supplementation in the lowering of glycemia in diabetes remains to be determined.

191 and is the standard measure used to monitor glycemia in diabetic patients, but results from studies

192 aches to normalize the extreme volatility of glycemia in diabetic patients.

193 nally, glucagon receptor antagonist improves glycemia in diet-induced obese angptl4 knockout mice wit

194 tion of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers.

195 stprandial insulin release is independent of glycemia in healthy individuals, despite differences in

196 beneficial effects of probiotics on maternal glycemia in healthy pregnant women.

197 eline were unaffected by acute variations in glycemia in healthy subjects and in type 2 diabetic pati

198 ubjects, providing the opportunity to reduce glycemia in human subjects with diabetes with a low risk

199 tor play a role in the regulation of fasting glycemia in K(ATP)HI; and 2) the GLP-1 receptor may be a

200 at accumulation, despite a similar impact on glycemia in male ZDF rats.

201 Glycemia in non-fasted mice was measured weekly from day

202 isms accounting for this improved control of glycemia in overweight adults under conditions of one da

203 ter insulin sensitivity in healthy adults or glycemia in patients with diabetes.

204 determine the role of GLP-1 in postprandial glycemia in patients with hyperinsulinemic hypoglycemia

205 Salsalate improves glycemia in patients with T2DM and decreases inflammator

206 cid sequestrant colesevelam HCl for reducing glycemia in patients with T2DM.

207 s combination will reduce weight and improve glycemia in patients.

208 ydrate exchange in the dietary management of glycemia in persons with diabetes, and studies have gene

209 1x10-4), which results in increased maternal glycemia in pregnancy and hence increased offspring birt

210 gh maternal genotype, by increasing maternal glycemia in pregnancy, or through fetal genotype, by alt

211 Air pollution may contribute to abnormal glycemia in pregnancy.

212 are associated with quantitative measures of glycemia in pregnancy.

213 characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied w

214 Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated

215 ivo because mouse beta-cells restored normal glycemia in streptozotocin-induced diabetic mice and hum

216 insulin; this led to a steady correction of glycemia in the subsequent days.

217 The normalization of the glycemia in the transplanted mice was associated with no

218 suggests a plausible mechanism for elevated glycemia in these mice.

219 uration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM).

220 Current approaches to assessing glycemia include the use of self-monitoring of blood glu

221 tal cancer cells); reduction in postprandial glycemia; increased insulin sensitivity; and effects on

222 glucagon-like peptide-1 (GLP-1), might lower glycemia independent of increased beta-cell response or

223 ation of intestinal ECS reduced postprandial glycemia independently on intestinal glucose transport b

224 the gluconeogenic gene program, and lowered glycemia, indicating that a similar phenomenon occurs in

225 luenced: HDL-cholesterol, LDL particle size, glycemia, insulinemia, inflammatory biomarkers, blood pr

226 The regulation of glycemia is challenged in healthy men and women after ex

227 paired; 2) the effect of DPP-4 inhibition on glycemia is likely to depend on adequate endogenous GLP-

228 nt expression of proinflammatory genes after glycemia is normalized ("hyperglycemic memory").

229 Comprehensive recording of glycemia is required for the generation of any measureme

230 behind blood glucose, regardless of whether glycemia is rising or falling, but intersensor variabili

231 rbohydrate content, even though postprandial glycemia is vastly influenced by glycemic index (GI).

232 on of T cells, when combined with control of glycemia, is thus able to effect an apparent cure of est

233 as insulin sensitivity based on postprandial glycemia [ISI(gly), r(s) = 0.58, P < 0.05], whereas the

234 se healthy patients) with no gradient across glycemia levels (20.6% of those with HbA1C<6%, 17.3% of

235 5 mmol/L, on 3 separate days, twice at lower glycemia (LOW) and once at higher values (HIGH).

236 onally adjusting for the latent variable for glycemia, low 1,5-AG levels (<6.0 mug/mL) were no longer

237 lobin levels and other indicators of average glycemia may be due to many factors but can be measured

238 in insulin secretion according to prevailing glycemia may improve diagnostic accuracy.

239 over time, the allostatic load (increase in glycemia) may have pathological consequences, such as th

240 The association of chronic glycemia, measured by HbA(1c), with long-term complicati

241 inuria, or albuminuria is due to elements of glycemia not captured by mean HbA1c values.

242 rovide 90% power and a difference in fasting glycemia of 0.25 mmol/L.

243 study was to determine the effect of plasma glycemia on the incretin effect.

244 A cycle activity but failed to lower fasting glycemia or endogenous glucose production.

245 with insulin resistance but not with fasting glycemia or glucose intolerance.

246 nd no effect of vitamin D supplementation on glycemia or incident diabetes.

247 r-expressing Ldlr(-/-) mice independently of glycemia or plasma levels of total cholesterol and trigl

248 Hemoglobin A1c (HbA1c) reflects glycemia over 2-3 months and is the standard measure use

249 ositive effect of regular SMBG for improving glycemia, particularly in individuals treated with insul

250 eptor agonist exenatide reduces postprandial glycemia, partly by slowing gastric emptying, although i

251 REM and AHINREM were associated with fasting glycemia, post-prandial glucose levels, and HOMA-IR in m

252 en without being able to reduce postprandial glycemia, products with slowly digestible starch can hav

253 rom 4 to100 mM (covering the hypo- and hyper-glycemia range, useful in diabetes).

254 mine and histidine decreased with increasing glycemia, reflecting, at least in part, insulin resistan

255 These neo-islets display glycemia-regulated insulin, beta-cell-specific transcrip

256 understand whether efficacy was mediated by glycemia regulation, a comparison with the sulfonylurea

257 abetic female NOD mice using measurements of glycemia, regulatory T-cell (CD4+CD25+Foxp3+) frequency,

258 ms that initiate adrenocortical responses to glycemia-related challenges are unknown.

259 tiate the adrenocortical response to various glycemia-related challenges.

260 Hindbrain catecholamine neurons distribute glycemia-related information throughout the forebrain.

261 lease of dietary glucose, is associated with glycemia-related problems such as diabetes and other met

262 imeglimin treatment significantly decreased glycemia, restored normal glucose tolerance, and improve

263 in response plays a limited role in improved glycemia shortly after surgery.

264 ormin reduced fasting and glucose-stimulated glycemia, suppressed energy intake, and augmented total

265 maintained more stable afternoon and evening glycemia than did fasting.

266 (Pla2g1b) gene displayed lower postprandial glycemia than that observed in wild-type mice after bein

267 re the improvement in insulin resistance and glycemia that appears to occur with PHT in women with AG

268 ckade in the intestine reduced the increased glycemia that occurs following oral glucose administrati

269 ing macronutrient and modulates postprandial glycemia; the comparative effects of intraduodenal prote

270 ngle subcutaneous injection of BMP-9 reduced glycemia to near-normal levels, with maximal reduction o

271 The effect of the randomized glycemia treatment on clinical and health status outcome

272 In the glycemia trial, targets of intensive and standard treatm

273 iodontal examination and preprandial fasting glycemia values were recorded for each individual.

274 meal and act on local receptors to regulate glycemia via a neuronal gut-brain axis.

275 GLP-1 receptor (GLP-1R) agonists control glycemia via glucose-dependent mechanisms of action and

276 investigated whether GIP regulates GLP1 and glycemia via IL6.

277 e systematically higher levels of nonfasting glycemia warrants further study.

278 se production (EGP) was increased 25%, while glycemia was 0.9 +/- 0.7 mmol/l lower (P < 0.0001 vs. ba

279 To address this, glycemia was assessed in CFTR null (CFTR(-/-)), C57BL/6J

280 tive in reversing diabetes in NOD mice whose glycemia was controlled with SC insulin pellets; these e

281 Moreover, postmeal glycemia was elevated and insulin release was blunted in

282 ce with streptozotocin-induced diabetes, and glycemia was initially controlled with exogenous insulin

283 o hyperinsulinemic-hypoglycemic clamps where glycemia was lowered slowly over 60-75 min.

284 Glycemia was measured by a glucose-oxidase method and bl

285 Glycemia was monitored to determine disease prevention a

286 ed on the NOD/ShiLtJ genetic background, and glycemia was monitored weekly up to 35 weeks of age to d

287 Continuously measured glycemia was more variable during the afternoon and even

288 compared with sham in wild-type mice, while glycemia was not altered in CRF(1)-deficient mice.

289 ion of retinopathy by intensive treatment of glycemia was observed in ACCORD participants, whose aver

290 Glycemia was unaffected.

291 onventional diabetes diet recommendations on glycemia, weight, and plasma lipids.

292 rance tests (OGTTs) from differing states of glycemia were compared within individuals for glucose an

293 t neurologic insult; biochemical measures of glycemia were less consistently related to MR imaging ch

294 Sustained benefits in glycemia were not identified following HCV clearance irr

295 led device camera, immunohistochemistry, and glycemia were used to assess islet engraftment and funct

296 ect was accompanied by improvement in plasma glycemia, whole body insulin sensitivity, plasma lipid l

297 terrelationships among different measures of glycemia will need to be considered in future analyses o

298 ing and opposite associations of gestational glycemia with weight and BMI in the first 36 mo of life

299 en developed that reflects the constraint of glycemia within narrow physiologic limits.

300 ffecting other FOXO1 target genes and lowers glycemia without concurrent steatosis.